| scholarly article | Q13442814 |
| P50 | author | Paul A Gurbel | Q89230591 |
| P2093 | author name string | Ashwani K Bassi | |
| Joseph DiChiara | |||
| Kevin P Bliden | |||
| Srivasavi K Chaganti | |||
| Udaya S Tantry | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | platelet aggregation | Q14913634 |
| patient | Q181600 | ||
| clopidogrel | Q410237 | ||
| P304 | page(s) | 657-66 | |
| P577 | publication date | 2007-02-13 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? | |
| P478 | volume | 49 |
| Q46624023 | "Short" thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: validation and reproducibility |
| Q37550156 | A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes |
| Q55473805 | Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis. |
| Q34111144 | Adenosine diphosphate–induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic events |
| Q38958862 | Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors |
| Q37437158 | Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements |
| Q37882712 | Antiplatelet drug therapy: role of pharmacodynamic and genetic testing |
| Q37914924 | Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents |
| Q37684794 | Antiplatelet therapies for the treatment of cardiovascular disease |
| Q36932221 | Aspirin and clopidogrel response variability: review of the published literature |
| Q36720281 | Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus |
| Q53163564 | Association of ABCB1 promoter methylation with aspirin exposure, platelet function, and clinical outcomes in Chinese intracranial artery stenosis patients. |
| Q35921906 | Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting |
| Q34019082 | Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy |
| Q48146410 | Association of thrombelastographic parameters with post-stenting ischemic events |
| Q37067222 | Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke |
| Q35707491 | Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study. |
| Q35959359 | Both PON1 Q192R and CYP2C19*2 influence platelet response to clopidogrel and ischemic events in Chinese patients undergoing percutaneous coronary intervention |
| Q36477309 | CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome |
| Q36800844 | Clinical characteristics associated with high on-treatment platelet reactivity of patients undergoing PCI after a 300 mg loading dose of clopidogrel, measured by thrombelastography |
| Q34390050 | Clinical importance of aspirin and clopidogrel resistance |
| Q37841560 | Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention |
| Q57098373 | Clopidogrel discontinuation and platelet reactivity following coronary stenting |
| Q43110182 | Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial |
| Q36804776 | Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel |
| Q37364537 | Contemporary issues on clopidogrel therapy |
| Q53471405 | Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. |
| Q48839146 | Correlation of pre-operative plasma protein concentrations in cardiac surgery patients with bleeding outcomes using a targeted quantitative proteomics approach |
| Q33760816 | Correlations between High Platelet Reactivity, Extent of Coronary Artery Disease, and Periprocedural Myonecrosis in Patients with Acute Coronary Syndrome |
| Q34382431 | Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents |
| Q34910745 | Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study |
| Q92355966 | DT-678 inhibits platelet activation with lower tendency for bleeding compared to existing P2Y12 antagonists |
| Q42871091 | Determination of the Prevalence of Aspirin and Clopidogrel Resistances in Patients with Coronary Artery Disease by using Various Platelet-function Tests |
| Q39025194 | Does the response to aspirin and clopidogrel vary over 6 months in patients with ischemic heart disease? |
| Q37752222 | Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. |
| Q34983154 | Drug-drug interaction between clopidogrel and the proton pump inhibitors. |
| Q50980833 | Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience. |
| Q84752652 | Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents |
| Q37396871 | Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study |
| Q44075675 | Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention |
| Q46367587 | Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. |
| Q37988850 | Evolving role of platelet function testing in coronary artery interventions |
| Q38396605 | Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis |
| Q37602843 | Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity |
| Q37291972 | Head to Head Comparison of Two Point-of-care Platelet Function Tests Used for Assessment of On-clopidogrel Platelet Reactivity in Chinese Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention |
| Q30450312 | High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study |
| Q26824850 | High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance |
| Q34211191 | Hostility and platelet reactivity in individuals without a history of cardiovascular disease events |
| Q46472467 | Hypercoagulation assessed by thromboelastography is neither related to infarct size nor to clinical outcome after primary percutaneous coronary intervention |
| Q37203987 | Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome |
| Q36078210 | Impact of platelet function test on platelet responsiveness and clinical outcome after coronary stent implantation: platelet responsiveness and clinical outcome |
| Q45247864 | Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). |
| Q38154612 | Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account |
| Q35796575 | In Vitro Assessment of Cytochrome P450 2C19 Potential of Naoxintong |
| Q57098021 | Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy |
| Q42512335 | Inhibition of platelet aggregation ex vivo is repressed in apolipoprotein E deficient mice. |
| Q45918033 | Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. |
| Q37234094 | Interaction between statins and clopidogrel: is there anything clinically relevant? |
| Q37378896 | Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Wo |
| Q37164391 | Investigating the mechanisms of hyporesponse to antiplatelet approaches |
| Q39021950 | Is arachidonic acid stimulation really a test for the response to aspirin? Time to think again? |
| Q37910837 | Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods |
| Q38012079 | Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention |
| Q40000465 | Mild hypothermia does not attenuate platelet aggregation and may even increase ADP-stimulated platelet aggregation after clopidogrel treatment |
| Q46800789 | Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism |
| Q38099235 | Monitoring aspirin and clopidogrel response: testing controversies and recommendations |
| Q35373683 | Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations |
| Q34532327 | New Developments in Platelet Cyclic Nucleotide Signalling: Therapeutic Implications. |
| Q41511099 | P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon? |
| Q37339517 | P2Y12 inhibitors in cardiovascular disease: focus on prasugrel |
| Q37642822 | Personalized antiplatelet therapy for coronary artery disease patients: is this the future? |
| Q26775125 | Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls |
| Q38116753 | Pharmacogenomics of anti-platelet and anti-coagulation therapy |
| Q27022443 | Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? |
| Q37927151 | Pharmacokinetic basis of the antiplatelet action of prasugrel |
| Q34019342 | Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers |
| Q43187673 | Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects |
| Q82365821 | Platelet Function Measured Using a Whole Blood Aggregometer Can Predict Bleeding Events |
| Q37678656 | Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions |
| Q38007894 | Platelet function and inhibition in ischemic heart disease |
| Q38089082 | Platelet function tests for the monitoring of P2Y12 inhibitors |
| Q44621004 | Platelet function: new drugs, new assays : possible impacts on operative medicine? |
| Q48145829 | Platelet mapping as part of modified thromboelastography (TEG®) in patients undergoing cardiac surgery and cardiopulmonary bypass |
| Q57734957 | Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis |
| Q27010236 | Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis |
| Q47411283 | Point-of-care platelet function testing to predict blood loss after coronary artery bypass grafting surgery: a prospective observational pilot study |
| Q37749813 | Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease |
| Q44426942 | Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials. |
| Q41742863 | Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia. |
| Q42931790 | Pre-Procedural Platelet Reactivity After Clopidogrel Loading in Korean Patients Undergoing Scheduled Percutaneous Coronary Intervention |
| Q38456752 | Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial |
| Q37540088 | Recent developments in clopidogrel pharmacology and their relation to clinical outcomes |
| Q90084142 | Residual platelet reactivity is preferred over platelet inhibition rate in monitoring antiplatelet efficacy: insights using thrombelastography |
| Q37765291 | Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization |
| Q37807524 | Resistance to aspirin and clopidogrel therapy. |
| Q47834419 | Risk of bleeding and adverse outcomes predicted by thromboelastography platelet mapping in patients taking clopidogrel within 7 days of non-cardiac surgery |
| Q53085520 | Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists. |
| Q45381763 | Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction |
| Q41651465 | Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis |
| Q46947924 | Systematic evaluation of evidence on veterinary viscoelastic testing part 5: Nonstandard assays. |
| Q50983419 | The Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study: Variation in Platelet Response to Clopidogrel and Aspirin. |
| Q50921210 | The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA. |
| Q24653812 | The drug-drug interaction between proton pump inhibitors and clopidogrel |
| Q33893919 | The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study |
| Q42406128 | The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay |
| Q26824694 | The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysis |
| Q36589808 | Thromboelastography for monitoring platelet function in unruptured intracranial aneurysm patients undergoing stent placement |
| Q39040803 | Ticagrelor Compared with Clopidogrel Increased Adenosine and Cyclic Adenosine Monophosphate Plasma Concentration in Acute Coronary Syndrome Patients |
| Q37552005 | Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist |
| Q90647716 | Two common mutations within CYP2C19 affected platelet aggregation in Chinese patients undergoing PCI: a one-year follow-up study |
| Q38016384 | Use of cilostazol in percutaneous coronary interventions |
| Q39208503 | Use of thromboelastography to tailor dual-antiplatelet therapy in patients undergoing treatment of intracranial aneurysms with the Pipeline embolization device |
| Q30498026 | Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood |
| Q37704842 | What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel |
Search more.